Product Description
Mechanisms of Action: CB1 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Brazil | Chile | Colombia | European Medicines Agency | Germany | Hungary | India | Ireland | Italy | Peru | Portugal | Slovenia | Sweden | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Atherosclerosis|Obesity|Insulin Resistance|Healthy Volunteers|Inflammation|Other|Overweight|Diabetes, Gestational|Dyslipidemia|Obesity, Abdominal|Cocaine-Related Disorders|Alcoholism
Phase 3: Other|Obesity|Type 2 Diabetes|Weight Loss|Spinal Cord Injuries|Non-alcoholic Fatty Liver Disease|Fatty Liver, Alcoholic|Overweight|Smoking Cessation|Tobacco Use Disorder|Atherosclerosis|Coronary Artery Disease|Myocardial Ischemia|Myocardial Infarction|Albuminuria|Dyslipidemia|Obesity, Abdominal|Stroke|Prediabetic State|Schizophrenia|Metabolic Syndrome X|Arteriosclerosis|Carotid Stenosis|Glucose Intolerance|Prader-Willi Syndrome|Weight Gain|Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic
Phase 2: Spinal Cord Injuries|Alcoholic Intoxication|Psychotic Disorders|Obesity|Affective Disorders, Psychotic|Hypertension|Tobacco Use Disorder|Schizophrenia|Marijuana Abuse|Polycystic Ovary Syndrome
Phase 1: Marijuana Abuse
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2022-001522-30 | P3 |
Active, not recruiting |
Spinal Cord Injuries |
2024-09-29 |
|
| RIMOFATSCI-2 | P2 |
Unknown status |
Spinal Cord Injuries |
2023-11-01 |
|
| RIMOFATSCI-1 | P2 |
Completed |
Spinal Cord Injuries |
2022-06-07 |
|
| Effec Acomplia gastric sensitivity | P4 |
Completed |
Healthy Volunteers |
2021-03-03 |